1. Zhao J, Ueki M, Sawai S, Sugiyama M, Terashita Y, Hirabayashi S, Cho Y, Kobayashi R, Tanaka Y, Manabe A: The heterozygous NUDT15 variants is not associated with the severity of 6-mercapropurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia. Eur J Cancer Pediatr Oncol, in press
2. Tsujimoto SI, Sakamoto K, Nakano Y, Mizuno T, Shindo T, Watanabe J, Sato-Otsubo A, Osumi T, Matsumoto K, Tomizawa D, Kato M. Myelodysplastic syndrome in a patient with Barth syndrome (3-methylglutaconic aciduria type II). Pediatr Blood Cancer 2023, 70, e30033, doi:10.1002/pbc.30033.
3. Kato M. Recent progress in pediatric lymphoblastic leukemia. Int J Hematol 2023, 117, 155-161, doi:10.1007/s12185-022-03501-x.
4. Yoshida M, Brown SA, Moriyama T, Nishii R, Tsujimoto SI, Yamada Y, Yoshida K, Shirai R, Osumi T, Utano T, Fukano R, Kudo K, Sakaguchi K, Arakawa Y, Koh K, Sekiguchi M, Sekimizu M, Miyamura T, Ishida H, Inukai T, Tomizawa D, Kiyokawa N, Kato M, Yang JJ. Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance. Br J Haematol 2022, 199, 270-276, doi:10.1111/bjh.18375.
5. Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S. A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20). Jpn J Clin Oncol 2022, 52, 1225-1231, doi:10.1093/jjco/hyac105.
6. Shirai R, Osumi T, Sato-Otsubo A, Nakabayashi K, Mori T, Yoshida M, Yoshida K, Kohri M, Ishihara T, Yasue S, Imamura T, Endo M, Miyamoto S, Ohki K, Sanada M, Kiyokawa N, Ogawa S, Yoshioka T, Hata K, Takagi M, Kato M. Genetic features of B-cell lymphoblastic lymphoma with TCF3-PBX1. Cancer Rep (Hoboken) 2022, 5, e1559, doi:10.1002/cnr2.1559.
7. Shirai R, Osumi T, Sato-Otsubo A, Nakabayashi K, Ishiwata K, Yamada Y, Yoshida M, Yoshida K, Shioda Y, Kiyotani C, Terashima K, Tomizawa D, Takasugi N, Takita J, Miyazaki O, Kiyokawa N, Yoneda A, Kanamori Y, Hishiki T, Matsumoto K, Hata K, Yoshioka T, Kato M. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma. Genes Chromosomes Cancer 2022, 61, 662-669, doi:10.1002/gcc.23073.